title: Alpha-methyldopa-chlorpromazine combination in schizophrenic patients.
abstract: In a double-blind, controlled clinical study, lasting 8 weeks, 55 hospitalized schizophrenic patients were randomly assigned to one of the five drug treatments: 600 mg chlorpromazine/day, 300 mg chlorpromazine/day, 300 mg chlorpromazine--250 mg alpha-methyldopa/day, 300 mg chlorpromazine--500 mg alpha-methyldopa/day, 300 mg chlorpromazine--750 mg alpha-methyldopa/day. The results showed that all five treatments were significantly effective in treating schizophrenic behavior. The dose-response relationship for the different doses of alpha-methyldopa in combination with chlorpromazine, suggested an optimal response to 300 mg chlorpromazine--500 mg alpha-methyldopa.
mesh_terms: D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D002746:Chlorpromazine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008750:Methyldopa / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D010919:Placebos; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D010919:Placebos; D008750:Methyldopa; D002746:Chlorpromazine